Close Menu

NEW YORK – Three investment banks on Monday initiated coverage of rare disease genetic testing and services company Centogene with bullish outlooks.

BTIG initiated coverage of Rostock, Germany-based Centogene with a Buy rating on its stock and an $18 price target, while SVB Leerink rated the firm's shares Outperform and put a price target of $21. Evercore ISI began coverage of Centogene with an Outperform rating on its stock and a $17 price target.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.